Compare SRRK & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | AMRX |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.7B |
| IPO Year | 2018 | 2018 |
| Metric | SRRK | AMRX |
|---|---|---|
| Price | $42.47 | $12.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $55.40 | $14.75 |
| AVG Volume (30 Days) | 1.3M | ★ 1.9M |
| Earning Date | 03-03-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.40 |
| Revenue Next Year | $449.79 | $6.54 |
| P/E Ratio | ★ N/A | $53.66 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.71 | $6.69 |
| 52 Week High | $49.82 | $15.42 |
| Indicator | SRRK | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.45 | 34.79 |
| Support Level | $41.54 | $11.55 |
| Resistance Level | $42.54 | $12.12 |
| Average True Range (ATR) | 2.40 | 0.45 |
| MACD | 0.05 | -0.08 |
| Stochastic Oscillator | 38.83 | 19.21 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.